Vonoprazanversusconventional proton pump inhibitor-based triple therapy as first-line treatment againstHelicobacter pylori: A multicenter retrospective study in clinical practice

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase

(2015) D. R. Scott et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Letter: promising results ofHelicobacter pylorieradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy

(2015) T. Inaba et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

The Diagnostic Validity of Citric Acid-Free, High Dose13C-Urea Breath Test AfterHelicobacter pyloriEradication in Korea

(2015) Yong Hwan Kwon et al.   HELICOBACTER

Hp-normogram (normo-graham) for Assessing the Outcome ofH. pyloriTherapy: Effect of Resistance, Duration, and CYP2C19 Genotype

(2015) David Y. Graham   HELICOBACTER

Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan forHelicobacter pylori

(2015) Koji Kamiya et al.   JOURNAL OF DERMATOLOGY

Distribution of intestinal metaplasia as a predictor of gastric cancer development

(2015) Satoki Shichijo et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Effect ofHelicobacter pyloriEradication on Metachronous Gastric Cancer after Endoscopic Resection of Gastric Tumors: A Meta-Analysis

(2014) Seung Bae Yoon et al.   HELICOBACTER

Changes in the first lineHelicobacter pylorieradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (TokyoHelicobacter pyloristudy group)

(2014) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials

(2014) A. C. Ford et al.   BMJ-British Medical Journal

Helicobacter pylori Infection Is Strongly Associated With Gastric and Duodenal Ulcers in a Large Prospective Study

(2012) Ben Schöttker et al.   Clinical Gastroenterology and Hepatology

Gastric cancer risk according to the distribution of intestinal metaplasia and neutrophil infiltration

(2011) Kosuke Sakitani et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition

(2010) Masahiro Asaka et al.   HELICOBACTER

Annual Change of Primary Resistance to Clarithromycin among Helicobacter pylori Isolates from 1996 through 2008 in Japan

(2009) Noriyuki Horiki et al.   HELICOBACTER

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial

(2008) Kazutoshi Fukase et al.   LANCET